Literature DB >> 3535715

Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test.

E N Harris, J K Chan, R A Asherson, V R Aber, A E Gharavi, G R Hughes.   

Abstract

To determine the predictive value of the IgG anticardiolipin antibody (ACA) test for thrombosis, recurrent fetal loss, and thrombocytopenia, the clinical features of 121 patients with varying antibody levels were studied. When patients were grouped into high-positive, low-positive, and normal groups according to their ACA levels, there were strong statistical correlations with arterial thrombosis, venous thrombosis, fetal loss, thrombocytopenia, and a positive Coombs' test. At levels of 7 SD and above, the test was highly specific (greater than 80%) and predictive (greater than 70%) for thrombosis, thrombocytopenia, and recurrent fetal loss. This study suggests that the IgG ACA test may be a useful predictor for thrombosis, recurrent fetal loss, and thrombocytopenia in patients with autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535715

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  79 in total

Review 1.  Antiphospholipid antibodies and stroke.

Authors:  Stanley Tuhrim
Journal:  Curr Cardiol Rep       Date:  2004-03       Impact factor: 2.931

2.  Anticardiolipin antibodies in dogs.

Authors:  R Papini; O Pellegrini; C Rossini; G Guidi
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

3.  Antiphospholipid antibodies: which and when?

Authors:  R Cervera; J Font; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

Review 4.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

5.  Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients.

Authors:  R Cervera; J Font; A López-Soto; F Casals; L Pallarés; A Bové; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

6.  Anticardiolipin antibody levels in diabetic subjects with and without coronary artery disease.

Authors:  T J Hendra; E Baguley; E N Harris; M H Khamashta; R C Trembath; G R Hughes; J S Yudkin
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

Review 7.  [The heart in rheumatic diseases].

Authors:  C Specker
Journal:  Internist (Berl)       Date:  2007-03       Impact factor: 0.743

8.  Fetal loss treatment in patients with antiphospholipid antibodies.

Authors:  J Ordi; J Barquinero; M Vilardell; R Jordana; C Tolosa; A Selva; E Genover
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

Review 9.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

10.  Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients.

Authors:  Roozbeh Jamshid; Serati Ali Reza; Ghaderi Abbas; Afshariani Raha
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.